Avicanna Inc.
Avicanna is a Canadian biopharmaceutical company providing the global marketplace with advanced natural cannabinoid solutions through an evidence-based approach offered across several product platforms including API, medical, pharmaceutical, and dermacosmetic. Avicanna is focused on utilizing the scientific research related to plant-derived cannabinoid products through its internal research platforms and strategic collaborations.
Company details
Find locations served, office locations
- Business Type:
- Distributor
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Globally (various continents)
This company also provides solutions for other industrial applications.
Please, visit the following links for more info:
About Us
Avicanna is a Canadian biopharmaceutical company providing the global marketplace with advanced natural cannabinoid solutions through an evidence-based approach offered across several product platforms including API, medical, pharmaceutical, and dermacosmetic. As a multinational organization with vertical integration , Avicanna is focused on utilizing the scientific research related to plant-derived cannabinoid products through its internal research platforms and strategic collaborations with world-class research institutions.
Avicanna’s Rho Phyto brand includes advanced formulations in various doses and deliveries of plant-derived cannabinoid-based medical solutions backed by pre-clinical data and with focus on symptom management across several pathologies. The Rho Phyto brand is currently in commercialization stage in Canada through an exclusive partnership with Medical Cannabis by Shoppers (a subsidiary of Shoppers Drug Mart). Pura Earth, is Avicanna’s CBD derma-cosmetic consumer brand which was developed to maintain and improve the health and appearance of the skin. Pura Earth launched in the Colombian market in November 2019, has completed clinical studies on several products and is currently in expansion stage globally. Avicanna’s Pharmaceutical pipeline includes various pharmaceutical products with focus on dermatology, neurology and pain management including a topical cream for Epidermolysis Bullosa , a rare genetic skin disorder which afflicting children, which is currently under review and pending Health Canada’s approval to commence phase II-III clinical trials at the Hospital for Sick Kids in Toronto and sublingual delivery for neuropathic pain with expected commencement of phase II studies in late 2020.
Avicanna is growing its network of strategic relationships with best-in-class and market leading institutions, located around the world to assist with the achievement of its business objectives. This includes large-scale cultivation, which is dedicated to being environmentally sustainable, manufacturing and commercialization, scientific R&D, and clinical research. Overall, Avicanna is committed to providing the highest quality and best cannabinoid solutions to patients and consumers.
Our Mission and Vision
To provide unparalleled quality of natural cannabinoids solutions that foster informed communities and improve quality of life.
To be the global leader in natural cannabinoid solutions through an evidence-based biopharmaceutical approach.
- Collaboration: We believe in working together cooperatively, within diverse global teams along with our communities and partners to reach common objectives and goals effectively.
- Innovation: We proactively seek out and implement forward-looking ideas to develop and enhance solutions and operations across all business functions.
- Excellence: We strive to achieve and maintain best in class standards of quality across our entire value chain
- Responsibility: We hold ourselves accountable for our impact on both internal and external stakeholders across our economic, social and environmental activities.
Avicanna Advantage
- Comprehensive commercial portfolio – consumer retail, and medical cannabis
- Multinational with international foot-print – USA, Canada, and LATAM
- Partnership with Medical Cannabis by Shopper’s Drug Mart Inc. – RHO Phyto and Pura Earth branded nation-wide in Canada
- Cannabinoid drug development expertise – 20+ advanced commercial products and pharmaceutical pipeline
- World-Class collaborations – with leading Canadian academic and clinical institutions
- JLABS @ Toronto, Johnson & Johnson Innovation Centre in the MaRS Discovery District, R&D headquarters
- Two (2) Colombian majority-owned subsidiaries – cultivation footprint of 480,000 sq feet with industrial extraction capacity
- Organic and sustainable cultivation – ranked highest amongst global cannabis companies in a corporate sustainability assessment – issued by S&P Global in 2020